BMJ Open. Healthcare utilization by pregnant asthma patients in South Korea: a cohort study using a nationwide claims data
|
|
- Elfreda Lynch
- 5 years ago
- Views:
Transcription
1 Healthcare utilization by pregnant asthma patients in South Korea: a cohort study using a nationwide claims data Journal: Manuscript ID: bmjopen-0-00 Article Type: Research Date Submitted by the Author: 0-Apr-0 Complete List of Authors: Lee, Chang-Hoon; Seoul National University Hospital, Department of Internal Medicine Kim, Jimin; National Evidence-based Healthcare Collaborating Agency, Division for Healthcare Technology Assessment Research Jang, Eun Jin; Andong National University, Department of Information Statistics Kim, Yun Jung; National Evidence-based Healthcare Collaborating Agency, Division for Healthcare Technology Assessment Research Choi, Seongmi; National Evidence-based Healthcare Collaborating Agency, Division for Healthcare Technology Assessment Research Lee, Joon-Ho; Seoul National University Hospital, Department of Obstetrics and Gynecology Kim, Deog Kyeom; Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Department of Internal Medicine Yim, Jae-Joon; Seoul National University College of Medicine, Department of Internal Medicine Yoon, Hoil; Hoil Yoon, <b>primary Subject Heading</b>: Obstetrics and gynaecology Secondary Subject Heading: Obstetrics and gynaecology, Respiratory medicine Keywords: Asthma < THORACIC MEDICINE, EPIDEMIOLOGY, pregnancy, inhaled respiratory drugs : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
2 Page of The prevalence and treatment of healthcare utilization of pregnant asthma patients: a cohort study using a nationwide claims data Chang-Hoon Lee, M.D.,, Jimin Kim, MPh., Eun Jin Jang, Ph.D.,, Yun Jung Kim, MPh., Seongmi Choi, Ph.D.,, Joon-Ho Lee, M.D., Ph.D., Deog Kyeom Kim, M.D., Ph.D.,, Jae-Joon Yim, M.D.,, *, Ho Il Yoon, M.D., Ph.D. National Evidence-based Healthcare Collaborating Agency, Seoul, Republic of Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea Department of Information Statistics, Colloge of Natural Science, Andong National University, Andong, Republic of Korea Real Estate R&D Institute, Korea Appraisal Board, Daegu, Republic of Korea Department of Obstetrics and Gynecology, Seoul National University College of College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of College of Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Republic of Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-Si, Republic of Korea * Corresponding author: Ho Il Yoon, M.D., Ph.D. - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
3 Page of Associate professor, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital,, Gumi-Ro Beon-Gil, Bundang-Gu, Seongnam-Si, Gyeonggi-Do, -0, Republic of Korea. Tel: Fax: dextro@snu.ac.kr Key words: asthma; epidemiology; pregnancy; inhaled respiratory drugs of coauthors: Chang-Hoon Lee: kauri0@empal.com Jimin Kim: jimin@neca.re.kr Eun Jin Jang: jejstat@gmail.com Yun Jung Kim: indigo@neca.re.kr Seongmi Choi: edisil0@nate.com Joon-Ho Lee: doctor-joon@hanmail.net Deog Kyeom Kim: kimdkmd@gmail.com Jae-Joon Yim: yimjj@snu.ac.kr Word count:,0 - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
4 Page of ABSTRACT Objectives: Few nationwide population-based studies have been performed on the burden of asthma during pregnancy. We investigated the burden of asthma during pregnancy requiring healthcare utilization and its medical treatment in South Korea. Design: Cohort study Setting: Nationwide insurance claims database Participatns:,0, pregnant women who deliver in South Korea between 00 and 0 Outcomes: The prevalence and the exacerbation rates of asthma requiring healthcare utilization, and the prescription of anti-asthmatic drugs during pregnancy Results: The prevalence of asthma requiring healthcare utilization was 0.% among pregnant women. Among pregnant women with asthma requiring healthcare utilization,.% were hospitalized and treated with systemic steroids and short-acting β-agonists during pregnancy. Oral drugs were prescribed less during the rd trimester than during the st trimester (all P values for trends were <0.00). A significant number of patients with asthma were likely to stop taking anti-asthmatic drugs after becoming pregnant. Conclusions: The prevalence of asthma requiring healthcare utilization during pregnancy was not very high. However, a significant number of women were likely to stop taking antiasthmatic drugs and did experience exacerbations. - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
5 Page of STRENGTHS AND LIMITATIONS OF THIS STUDY - A study analyzing asthma requiring healthcare utilization during pregnancy with use of a large scale, nationwide database - A diagnosis of asthma was defined by ICD-0 code together with anti-asthmatic medication. - The results showed a significant number of patients were likely to stop taking drugs after becoming pregnant and the prescription of oral drugs were decreasing during pregnancy. - Asthma cases requiring healthcare utilization were only a part of the whole asthmatic pregnant women, but the results can show a real world healthcare utilization pattern of asthmatics during pregnancy. - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
6 Page of INTRODUCTION Asthma is an important health condition during pregnancy. Approximately % of pregnant women currently have asthma in US and.% of them experience an asthma attack. A prospective study also reported that the majority of pregnant women that seek respiratory specialists due to dyspnea are asthmatics or probable asthmatics. Asthma seems to increase the risk of low birth weight, pre-eclampsia, preterm delivery, and congenital malformations. There are also drug safety issues. For example, treatment with systemic corticosteroids during asthma could increase the risk of preeclampsia, low birth weight, and preterm delivery. Although several studies have reported that inhaled corticosteroids (ICSs) and β-agonists did not affect pregnancy outcomes, - many women commonly avoid asthma drugs during pregnancy because of these safety issues.,0 However, few nationwide population-based studies have been performed on the actual burden and treatment of asthma during pregnancy. In this study, we investigated the prevalence of patients with asthma who visited hospitals during pregnancy in South Korea, the incidence rates of exacerbations, and the actual medical treatment of these patients using a nationwide insurance claims database. - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
7 Page of METHODS Source of Data The Health Insurance Review and Assessment Service (HIRA, Seoul, Republic of Korea) is a governmental agency that examines the accuracy of claims for National Health Insurance (NHI) and National Medical Aid (NMA) in South Korea, which covers about the.% of the entire. million South Korean population. We used the HIRA database; the details regarding NHI and the NMA database were described elsewhere. Briefly, the HIRA database includes information regarding demographic variables and all the rendered medical services, along with diagnostic codes (International Statistical Classification of Diseases and Related Health Problems, 0 th edition code, ICD-0), and all the dispensed prescribed medications. The proportion of missing or out-of-range answers in terms of key fields, including drug names, quantity, date dispensed, and duration, was less than 0.% of the records. This study was approved by the ethics review committee of the National Evidencebased Healthcare Collaborating Agency, Seoul, Republic of Korea. Written informed consent was not provided by study subjects. Patient records/information was anonymized and deidentified before analysis. Analyses We defined a pregnancy if a claim about a delivery event was found. The initiation date of a pregnancy was calculated as the date 0 weeks before the delivery event. If a woman was pregnant more than once, only the first pregnancy was included in the analysis. In our study, we focused on patients with asthma requiring healthcare utilization (who visited hospitals and received physicians diagnosis and care). To increase the accuracy of diagnosis and to reduce - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
8 Page of a bias, asthma was defined in two ways: () definition : ICD-0 code J or J that should be repeated with at least a -month interval, and () definition : definition plus use of any asthma medication at least once. Asthma medication included inhaled corticosteroids (ICSs), ICS combined with inhaled long-acting β-agonists (ICS/LABAs), inhaled short-acting β- agonists (SABAs), leukotriene receptor antagonists (LTRAs), and theophylline. The prevelence of asthma requiring healthcare utilization during pregnancy were calculated as the number of asthma cases per 00 pregnancies (%). We also estimated the incidence rates of severe exacerbations of asthma. (the number of cases per pregnancy) We defined severe exacerbations in two ways: () a visit to the emergency room or hospitalization with a diagnosis of asthma, and () condition () plus treatment with systemic corticosteroids or SABAs. Asthma medications prescribed within weeks before the initiation date of pregnancy and those prescribed during each pregnancy trimester were also evaluated. All statistical analyses were performed using the SAS. software (SAS Institute, Cary, NC, US). - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
9 Page of RESULTS In total,,0, pregnant women (mean age, 0. ±.) were observed from 00 to 0. Of these,, asthma cases were diagnosed. (definition : the prevalence was 0.% in 00-00: 0.% in 00 and 0.% in 00) Among these, the number of asthma patients who were prescribed asthma drugs at least once during pregnancy was, (definition : the prevalence was 0.% in 00-00; 0.% in 00; and 0.% in 00). Table shows how many pregnant women with asthma experienced exacerbations. Among the total number of asthmatic pregnant women requiring healthcare utilization,.% visited the emergency department or the hospital due to asthma (incidence rate, 0. per pregnancy) and.% were treated with systemic steroids and SABA after visiting the emergency department or hospital due to asthma (incidence rate, 0.0 per pregnancy). Among the asthmatic pregnant women who were treated with asthma medications,.0% visited the ER or were hospitalized due to asthma (incidence rate, 0. per pregnancy) and 0.0% were treated with systemic steroids and SABA after visiting the emergency department or being hospitalized due to asthma (incidence rate, 0. per pregnancy). - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
10 Page of Table. The incidence of emergency room visits or hospitalization due to asthma exacerbation during pregnancy Definition : Among total pregnant women with asthma Number of patients with events (%) In the complete study period (n =,; 0.% among total pregnant women) () ER visit or hospitalization due to asthma () () + treated with systemic steroids or SABA In 00 (n =,; 0.% among total pregnant women) () ER visit or hospitalization due to asthma () () + treated with systemic steroids or SABA In 00 (n =,; 0.% among total pregnant women)) () ER visit or hospitalization due to asthma () () + treated with systemic steroids or SABA Definition : Definition AND treated with anti-asthma drugs In the complete study period (n =, ; 0.% among total pregnant women) () ER visit or hospitalization due to asthma () () + treated with systemic steroids or SABA In 00 (n =,; 0.% among total pregnant women) () ER visit or hospitalization due to asthma () () + treated with systemic steroids or SABA In 00 (n =,; 0.% among total pregnant women)) () ER visit or hospitalization due to asthma () () + treated with systemic steroids or SABA (.%) (.%) (.%) (.%) (.%) (.%) (.0%) (0.0%) (.%) (.%) 0 (.%) (0.%) Number of events Incidence rate (per pregnancy) : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
11 Page 0 of More than half of the pregnant women with asthma were prescribed either ICS/LABA (.%) or ICS alone (.%). The most commonly prescribed ICS/LABA was fluticasone/salmeterol (.%) and the most commonly used ICS was budesonide (.%). LTRA, theophylline, and systemic steroids were used in.0%,.%, and.% of cases, respectively. These oral drugs were less prescribed during the rd trimester than during the st trimester (all P values for trends were <0.00, Table ). Table. Asthma treatment among pregnant women with asthma (n =,) P for Total st trimester nd trimester** rd trimester*** trend n (%) n (%) n (%) n (%) ICS or LABA 0. Neither ICS nor LABA, (.%),0 (.%), (.0%),00 (.%) ICS with LABA,0 (.%) (.%) (.%) (.%) ICS without LABA,0 (.%) (.%) 0 (.%) (.%) LABA only (0.%) (0.%) (0.%) (0.%) ICS/LABA ICS LABA Fluticasone/salmeterol,0 (.%) (0.%) (0.%) 0 (.%) 0. Budesonide/formoterol (0.%) (.%) (.%) (.%) 0.0 Fluticasone (.%) 0 (0.%) (0.%) (0.%) 0. Budesonide, (.%) 0 (.%) (.%) (0.%) 0. other ICS (.%) (.0%) (.%) (.0%) 0. Salmeterol 0 (0.%) (0.%) (0.%) (0.%) 0.0 Formoterol (0.0%) 0 (0.0%) 0 (0.0%) (0.0%) 0. SABA,0 (.%) 0 (.%) (.%) (.%) 0.00 LTRA,0 (.0%),0 (.%) (.%) (.%) <0.00 Theophylline (.%) (.%) (.%) 0 (.%) <0.00 Systemic steroids 0 (.%) 0 (.%) (.%) 0 (.%) < : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
12 Page of To evaluate how asthma patients changed their treatment after pregnancy, we also analyzed,0 patients who had been diagnosed with asthma (ICD-0 code J-J one time) within years before pregnancy from the total cohort. Compared with the period within weeks just before pregnancy, the percentages of asthma medications after pregnancy decreased markedly (Table ). - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
13 Page of Table. Asthma medication before and after pregnancy among asthma suspects (n =,0) During pregnancy Before pregnancy Total st trimester nd trimester rd trimester Before vs. n (%) n (%) n (%) n (%) n (%) During None, (.%), (.%) 0,0 (.%), (.%), (.%) < 0.00 <0.00 ICS,0 (.%) (0.%) (0.%) 0 (0.%) (0.%) < ICS+LABA,0 (.%) 0 (.0%) (0.%) (0.%) (0.%) < LTRA, (.%), (.%), (.%) (0.%) (0.%) < 0.00 <0.00 ICS+LTRA,0 (.%) (0.%) 0 (0.%) (0.%) (0.%) < 0.00 <0.00 ICS+LABA+LTRA, (.%) (0.%) (0.%) 0 (0.%) 0 (0.%) < 0.00 <0.00 on March 0 by guest. Protected by copyright. - P value Trend during pregnancy : first published as 0./bmjopen-0-00 on November 0. Downloaded from
14 Page of DISCUSSION The prevalence rate of asthma requiring healthcare utilization during pregnancy was 0.% in South Korea. In a field survey conducted more than 0 years ago with a randomly recruited general population from cities and rural areas in Korea, the prevalence of current asthma, defined as a case with current wheeze and positive bronchial hyperresponsiveness, in participants years old was about %. Considering that only a small percentage of patients visit healthcare services, the prevalence in our study may be reasonable. The prevalence of asthma during pregnancy was comparable to or slightly lower than that in the previous report in which, based on the insurance database, the prevalence of asthma in the Korean general population aged 0 years was reported as.. cases per,000 persons. Significant numbers of pregnant women with asthma experienced severe exacerbation in our study. Among the women who were diagnosed with asthma,.% visited the ER or were admitted to a hospital due to asthma and.% were also treated with systemic steroids and SABA, which is consistent with the results of previous studies. - This could be associated with the general low rate of asthma medication use during pregnancy. Among the,0 asthma suspects who were diagnosed with asthma within years before pregnancy, only.% were prescribed asthma drugs at least once. The most common drugs for asthma during pregnancy in South Korea were ICS or ICS/LABA, similar to those administered to non-pregnant patients with asthma. When ICS alone was used, budesonide was more commonly selected during pregnancy than fluticasone, although fluticasone/salmeterol was more widely chosen than budesonide/formoterol. This might be influenced by the result of a subgroup analysis of a randomized controlled trial in which the safety of budesonide during pregnancy was shown. - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
15 Page of About one-third of these patients with asthma took anti-asthma drugs within weeks before pregnancy. Asthmatic women could have stopped anti-asthma drugs because asthmatic symptoms improve during pregnancy. However, it is well known that the percentages of people with improved, same, and worsened asthmatic symptoms during pregnancy are similar. Thus, many women may have stopped taking anti-asthma drugs after becoming pregnant, possibly due to concerns that these drugs could affect pregnancy outcomes, although it is widely accepted that it is safer for pregnant women with asthma to be treated with asthma medications than to continue to have asthma symptoms and exacerbations. Although no drug can, in fact, be considered completely safe, 0 the major anti-asthma drugs are generally regarded as safe - and uncontrolled asthma may be associated with poorer pregnancy outcomes.,, In fact, the guidelines state that poorly controlled asthma and exacerbations cause a much greater risk to the baby than current asthma treatments do. 0 Limitations of our study include that asthma cases requiring healthcare utilization were only a part of the whole asthmatic pregnant women. Because this study was not a survey but was based on a claims database, some mild asthmatic pregnant women who did not need to seek medical attention may not have been included in our analysis. But the results can show a real world healthcare utilization pattern of asthmatics during pregnancy. In conclusion, in this analysis by a nationwide insurance claims database, the prevalence of asthma requiring healthcare utilization during pregnancy was not very high. However, a significant number of women were likely to stop anti-asthmatic drugs and did experience exacerbations. - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
16 Page of ACKNOWLEDGEMENTS CONTRIBUTORS CHL, JK, and JHL wrote the manuscript. JK, YJK, EJJ, AND SMC analyzed data. DKK and JJY participated in study design. CHL and HIY planned the study. FUNDING This study was supported by the National Evidence-Based Healthcare Collaborating Agency (NA-00), which contributed to the study s design, conduct, and reporting. COMPETING INTERESTS There are no conflicts of interest to be declared. ETHICS APPROVAL This study was approved by the ethics review committee of the National Evidence-based Healthcare Collaborating Agency, Seoul, Republic of Korea. DATA SHARING STATEMENT No additional data available. - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
17 Page of REFERENCES. Kwon HL, Triche EW, Belanger K, et al. The epidemiology of asthma during pregnancy: prevalence, diagnosis, and symptoms. Immunol Allergy Clin North Am 00; :-. Bidad K, Heidarnazhad H, Pourpak Z, et al. Frequency of asthma as the cause of dyspnea in pregnancy. Int J Gynaecol Obstet 00; :0-. Murphy VE, Namazy JA, Powell H, et al. A meta-analysis of adverse perinatal outcomes in women with asthma. BJOG 0; :-. Murphy VE, Wang G, Namazy JA, et al. The risk of congenital malformations, perinatal mortality and neonatal hospitalisation among pregnant women with asthma: a systematic review and meta-analysis. BJOG 0; 0:-. Schatz M, Dombrowski MP, Wise R, et al. The relationship of asthma medication use to perinatal outcomes. J Allergy Clin Immunol 00; :00-. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 00; :0-. Silverman M, Sheffer A, Diaz PV, et al. Outcome of pregnancy in a randomized controlled study of patients with asthma exposed to budesonide. Ann Allergy Asthma Immunol 00; :-0. Tata LJ, Lewis SA, McKeever TM, et al. Effect of maternal asthma, exacerbations and asthma medication use on congenital malformations in offspring: a UK populationbased study. Thorax 00; :-. Malm H, Martikainen J, Klaukka T, et al. Prescription of hazardous drugs during pregnancy. Drug Saf 00; :-0 0. Vlastarakos PV, Manolopoulos L, Ferekidis E, et al. Treating common problems of the - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
18 Page of nose and throat in pregnancy: what is safe? Eur Arch Otorhinolaryngol 00; :-0. Lee CH, Kim K, Hyun MK, et al. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 0; :0-. Kim YK, Kim SH, Tak YJ, et al. High prevalence of current asthma and active smoking effect among the elderly. Clin Exp Allergy 00; :0-. Park HS, Choi GS, Cho JS, et al. Epidemiology and current status of allergic rhinitis, asthma, and associated allergic diseases in Korea: ARIA Asia-Pacific workshop report. Asian Pac J Allergy Immunol 00; :-. Schatz M, Dombrowski MP, Wise R, et al. Asthma morbidity during pregnancy can be predicted by severity classification. J Allergy Clin Immunol 00; :-. Stenius-Aarniala BS, Hedman J, Teramo KA. Acute asthma during pregnancy. Thorax ; :-. Firoozi F, Ducharme FM, Lemiere C, et al. Effect of fetal gender on maternal asthma exacerbations in pregnant asthmatic women. Respir Med 00; 0:-. Bakhireva LN, Schatz M, Jones KL, et al. Asthma control during pregnancy and the risk of preterm delivery or impaired fetal growth. Ann Allergy Asthma Immunol 00; 0:-. Gluck JC. The change of asthma course during pregnancy. Clin Rev Allergy Immunol 00; :-0. Dombrowski MP, Schatz M, Bulletins-Obstetrics ACoP. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 0, February 00: asthma in pregnancy. Obstet Gynecol 00; :- 0. Global Initiative for Asthma. Global strategy for asthma management and prevention : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
19 Page of Section/Topic Item # STROBE 00 (v) Statement Checklist of items that should be included in reports of cohort studies Recommendation Reported on page # Title and abstract (a) Indicate the study s design with a commonly used term in the title or the abstract #, # Introduction (b) Provide in the abstract an informative and balanced summary of what was done and what was found # Background/rationale Explain the scientific background and rationale for the investigation being reported # Objectives State specific objectives, including any prespecified hypotheses # Methods Study design Present key elements of study design early in the paper # Setting Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Participants (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up # (b) For matched studies, give matching criteria and number of exposed and unexposed Variables Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if Data sources/ measurement applicable * For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Bias Describe any efforts to address potential sources of bias #- Study size 0 Explain how the study size was arrived at N/A (just a Quantitative variables Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Statistical methods (a) Describe all statistical methods, including those used to control for confounding # on March 0 by guest. Protected by copyright. (b) Describe any methods used to examine subgroups and interactions - # N/A # #- nationwide data) # N/A (we did not apply any subgroup analysis or analysis to find interactions) : first published as 0./bmjopen-0-00 on November 0. Downloaded from
20 Page of Results Participants Descriptive data (c) Explain how missing data were addressed N/A (we could not identify if missing exists ) (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses * (a) Report numbers of individuals at each stage of study eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed N/A N/A (our results are only descriptive) # (b) Give reasons for non-participation at each stage # (c) Consider use of a flow diagram We did not use a flow diagram * (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential # confounders (b) Indicate number of participants with missing data for each variable of interest N/A (we could not identify if missing exists ) (c) Summarise follow-up time (eg, average and total amount) # Outcome data * Report numbers of outcome events or summary measures over time #- Main results (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, % confidence #- interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized #- (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Other analyses Report other analyses done eg analyses of subgroups and interactions, and sensitivity analyses N/A Discussion Key results Summarise key results with reference to study objectives # Limitations Interpretation 0 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from #- similar studies, and other relevant evidence Generalisability Discuss the generalisability (external validity) of the study results # - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright. N/A
21 Page 0 of Other information Funding Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on # which the present article is based *Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at Annals of Internal Medicine at and Epidemiology at Information on the STROBE Initiative is available at : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
22 Healthcare utilization by pregnant asthma patients in South Korea: a cohort study using a nationwide claims data Journal: Manuscript ID bmjopen-0-00.r Article Type: Research Date Submitted by the Author: -Aug-0 Complete List of Authors: Lee, Chang-Hoon; Seoul National University Hospital, Department of Internal Medicine Kim, Jimin; National Evidence-based Healthcare Collaborating Agency, Division for Healthcare Technology Assessment Research Jang, Eun Jin; Andong National University, Department of Information Statistics Kim, Yun Jung; National Evidence-based Healthcare Collaborating Agency, Division for Healthcare Technology Assessment Research Choi, Seongmi; National Evidence-based Healthcare Collaborating Agency, Division for Healthcare Technology Assessment Research Lee, Joon-Ho; Seoul National University Hospital, Department of Obstetrics and Gynecology Kim, Deog Kyeom; Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Department of Internal Medicine Yim, Jae-Joon; Seoul National University College of Medicine, Department of Internal Medicine Yoon, Hoil; Hoil Yoon, <b>primary Subject Heading</b>: Obstetrics and gynaecology Secondary Subject Heading: Obstetrics and gynaecology, Respiratory medicine Keywords: Asthma < THORACIC MEDICINE, EPIDEMIOLOGY, pregnancy, inhaled respiratory drugs : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
23 Page of Healthcare utilization by pregnant asthma patients in South Korea: a cohort study using a nationwide claims data Chang-Hoon Lee, M.D.,, Jimin Kim, MPh., Eun Jin Jang, Ph.D.,, Yun Jung Kim, MPh., Seongmi Choi, Ph.D.,, Joon-Ho Lee, M.D., Ph.D., Deog Kyeom Kim, M.D., Ph.D.,, Jae-Joon Yim, M.D.,, *, Ho Il Yoon, M.D., Ph.D. National Evidence-based Healthcare Collaborating Agency, Seoul, Republic of Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea Department of Information Statistics, Colloge of Natural Science, Andong National University, Andong, Republic of Korea Real Estate R&D Institute, Korea Appraisal Board, Daegu, Republic of Korea Department of Obstetrics and Gynecology, Seoul National University College of College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of College of Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Republic of Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-Si, Republic of Korea * Corresponding author: Ho Il Yoon, M.D., Ph.D. - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
24 Page of Associate professor, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital,, Gumi-Ro Beon-Gil, Bundang-Gu, Seongnam-Si, Gyeonggi-Do, -0, Republic of Korea. Tel: Fax: dextro@snu.ac.kr Key words asthma; epidemiology; pregnancy; inhaled respiratory drugs of coauthors: Chang-Hoon Lee: kauri0@empal.com Jimin Kim: jimin@neca.re.kr Eun Jin Jang: jejstat@gmail.com Yun Jung Kim: indigo@neca.re.kr Seongmi Choi: edisil0@nate.com Joon-Ho Lee: doctor-joon@hanmail.net Deog Kyeom Kim: kimdkmd@gmail.com Jae-Joon Yim: yimjj@snu.ac.kr - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
25 Page of ABSTRACT Objectives: Few nationwide population-based studies have examined the burden of asthma during pregnancy. Here we investigated the burden and medical treatment of asthma during pregnancy requiring healthcare utilization in South Korea. Design: Cohort study Setting: Nationwide insurance claims database Participants: A total of,0, pregnant women who delivered in South Korea in 00 0 Outcomes: The prevalence and exacerbation rates of asthma requiring healthcare utilization, and the prescription of anti-asthmatic drugs during pregnancy Results: The prevalence of asthma requiring healthcare utilization was 0.% among pregnant women. Among those with asthma requiring healthcare utilization,.% were hospitalized and treated with systemic steroids and short-acting β -agonists during pregnancy. Oral drugs were prescribed less during the rd trimester than during the st trimester (all P values for trends were <0.00). A significant number of patients with asthma were likely to stop taking anti-asthmatic drugs after becoming pregnant. Conclusions: The prevalence of asthma requiring healthcare utilization during pregnancy was not very high. However, a significant number of women were likely to stop taking antiasthmatic drugs, and those who did tended to experience exacerbations. - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
26 Page of STRENGTHS AND LIMITATIONS OF THIS STUDY - A study analysing asthma requiring healthcare utilization during pregnancy using a largescale nationwide database - The diagnosis of asthma was defined as its ICD-0 code together with the patient s use of anti-asthmatic medication. - The results showed that a significant number of patients were likely to stop taking drugs after becoming pregnant and that the prescription of oral drugs decreased during pregnancy. - Although only a portion of the asthmatic pregnant women required healthcare utilization, our results showed a real world healthcare utilization pattern of asthmatics during pregnancy. - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
27 Page of INTRODUCTION Asthma is an important health condition during pregnancy. Approximately % of pregnant women in the US currently have asthma, and.% of them experience at least one asthma attack. One prospective study also reported that the majority of pregnant women who seek respiratory specialist care for dyspnoea are asthmatics or probable asthmatics. Asthma seems to increase the risk of low birth weight, pre-eclampsia, preterm delivery, and congenital malformations. Patients with asthma are also susceptible to drug safety issues. For example, treatment with systemic corticosteroids during asthma could increase the risk of preeclampsia, low birth weight, and preterm delivery. Although several studies have reported that inhaled corticosteroids (ICSs) and β-agonists did not affect pregnancy outcomes, - many women commonly avoid taking asthma drugs during pregnancy because of these safety issues.,0 However, few nationwide population-based studies have been performed of the actual burden and treatment of asthma during pregnancy. The national insurance program of South Korea covers more than % of Koreans. Although the prevalence of asthma among people aged 0 years old is reportedly 0. %,, that of asthma among pregnant women has never been investigated. In this study, we investigated the prevalence of asthma requiring healthcare utilization during pregnancy in South Korea, incidence of severe asthma exacerbations, and actual medical treatment of these patients using a nationwide insurance claims database. - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
28 Page of METHODS Data Source The Health Insurance Review and Assessment Service (HIRA, Seoul, Republic of Korea) is a governmental agency that examines the accuracy of claims submitted to the National Health Insurance (NHI) and National Medical Aid (NMA) in South Korea, which covers approximately.% of the entire. million South Korean population. We used the HIRA database, which includes information regarding demographic variables and all of the rendered medical services along with diagnostic codes (International Statistical Classification of Diseases and Related Health Problems, 0 th edition code, ICD-0), and all of the dispensed prescribed medications. The proportion of missing or out-of-range answers in terms of key fields, including drug names, quantity, date dispensed, and duration, comprised <0.% of the records. This study was approved by the ethics review committee of the National Evidencebased Healthcare Collaborating Agency, Seoul, Republic of Korea. Written informed consent was not required due to the study s retrospective nature. Patient records and information were anonymized and de-identified prior to the analysis. Analyses We identified a pregnancy whenever a claim about a delivery event was found. The initiation pregnancy date was calculated as the date 0 weeks before the delivery event. If a woman was pregnant more than once, only the first pregnancy was included in the analysis. In our study, we focused on patients with asthma that required healthcare utilization (who visited hospitals and received a physician s diagnosis and care). To increase the diagnostic accuracy and reduce bias, asthma was defined in two ways: () definition : ICD-0 code J or J - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
29 Page of that was repeated with at least a -month interval; and () definition : definition plus use of any asthma medication at least once. Asthma medication included ICSs, ICS combined with inhaled long-acting β-agonists (ICS/LABAs), inhaled short-acting β-agonists (SABAs), leukotriene receptor antagonists (LTRAs), and theophylline. The prevalence of asthma requiring healthcare utilization during pregnancy was calculated as the number of asthma cases per 00 pregnancies (%). We also estimated the incidence rates of severe exacerbations of asthma (number of cases per pregnancy). We defined severe exacerbations in two ways: () a visit to the emergency room or hospitalization with a diagnosis of asthma and () condition plus treatment with systemic corticosteroids or SABAs. Asthma medications prescribed within weeks before the initiation date of pregnancy and those prescribed during each pregnancy trimester were also evaluated. We evaluated whether there were significant trends across trimesters in the use of medications using Mantel-Haenszel statistics. All analyses were performed using SAS. software (SAS Institute, Cary, NC, US) and Stata. software (StataCorp, College Station, TX, US). - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
30 Page of RESULTS A total of,0, pregnant women (mean age, 0. ±. years) were observed in Of them,, were diagnosed with asthma (definition prevalence of 0.% in 00 00: 0.% in 00, 0.% in 00). Among them,, were prescribed asthma drugs at least once during pregnancy (definition prevalence of 0.% in 00 00: 0.% in 00 and 0.% in 00). Table shows how many pregnant women with asthma experienced exacerbations. Among the total number of asthmatic pregnant women requiring healthcare utilization,.% visited the emergency department or were admitted to the hospital for asthma treatment (incidence, 0. per pregnancy) and.% were treated with systemic steroids and SABA after visiting the emergency department or hospitalized for asthma treatment (incidence, 0.0 per pregnancy). Among the asthmatic pregnant women who were treated with asthma medications,.0% visited the emergency department or were hospitalized for asthma treatment (incidence, 0. per pregnancy) and 0.0% were treated with systemic steroids and SABA after visiting the emergency department or being hospitalized for asthma treatment (incidence, 0. per pregnancy). - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
31 Page of Table. The incidence of emergency room visits or hospitalization for asthma exacerbations during pregnancy Definition : Among all pregnant women with asthma Number of patients with events (%) In the complete study period (n =,; 0.% among all pregnant women) () ER visit or hospitalization for asthma treatment () condition + treatment with systemic steroids or SABA In 00 (n =,; 0.% of all pregnant women) () ER visit or hospitalization due to asthma () condition + treatment with systemic steroids or SABA In 00 (n =,; 0.% of all pregnant women) () ER visit or hospitalization for asthma treatment () condition + treatment with systemic steroids or SABA Definition : Definition AND treatment with anti-asthmatic drugs In the complete study period (n =,; 0.% of all pregnant women) () ER visit or hospitalization due to asthma () condition + treatment with systemic steroids or SABA In 00 (n =,; 0.% of all pregnant women) () ER visit or hospitalization for asthma treatment () condition + treatment with systemic steroids or SABA In 00 (n =,; 0.% of all pregnant women) () ER visit or hospitalization due to asthma () condition + treatment with systemic steroids or SABA ER: emergency room, SABA: short-acting β-agonists (.%) (.%) (.%) (.%) (.%) (.%) (.0%) (0.0%) (.%) (.%) 0 (.%) (0.%) Number of events Incidence (per pregnancy) : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
32 Page 0 of More than half of the pregnant women with asthma were prescribed either ICS/LABA (.%) or ICS alone (.%). The most commonly prescribed ICS/LABA was fluticasone/salmeterol (.%), while the most commonly used ICS was budesonide (.%). LTRA, theophylline, and systemic steroids were used in.0%,.%, and.% of cases, respectively. These oral drugs were less prescribed during the rd trimester than during the st trimester (all P values for trends were <0.00; Table ). Table. Asthma treatment among pregnant women with asthma (n =,) Total st trimester nd trimester** rd P for trimester*** trend n (%) n (%) n (%) n (%) ICS or LABA 0. Neither ICS nor LABA, (.%),0 (.%), (.0%),00 (.%) LABA only (0.%) (0.%) (0.%) (0.%) ICS without LABA,0 (.%) (.%) 0 (.%) (.%) ICS with LABA,0 (.%) (.%) (.%) (.%) ICS/LABA ICS LABA Fluticasone/salmeterol,0 (.%) (0.%) (0.%) 0 (.%) 0. Budesonide/formoterol (0.%) (.%) (.%) (.%) 0.0 Fluticasone (.%) 0 (0.%) (0.%) (0.%) 0. Budesonide, (.%) 0 (.%) (.%) (0.%) 0. Other ICS (.%) (.0%) (.%) (.0%) 0. Salmeterol 0 (0.%) (0.%) (0.%) (0.%) 0.0 Formoterol (0.0%) 0 (0.0%) 0 (0.0%) (0.0%) 0. SABA,0 (.%) 0 (.%) (.%) (.%) 0.00 LTRA,0 (.0%),0 (.%) (.%) (.%) <0.00 Theophylline (.%) (.%) (.%) 0 (.%) <0.00 Systemic steroids 0 (.%) 0 (.%) (.%) 0 (.%) <0.00 ICS: inhaled corticosteroids, LABA: long-acting β-agonists, SABA: short-acting β-agonists, LTRA: leukotriene receptor antagonists - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
33 Page of To evaluate how asthma patients changed their treatment compliance after pregnancy, we also analysed,0 patients from the overall cohort who were diagnosed with asthma (ICD-0 code J-J on at least one occasion) within years before pregnancy. Compared with the period within weeks just before pregnancy, the date of asthma medication use during pregnancy was markedly decreased (Table ). - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
34 Page of Table. Asthma medication before and after pregnancy among asthma suspects (n =,0) During pregnancy Before pregnancy Total st trimester nd trimester rd trimester Before vs. n (%) n (%) n (%) n (%) n (%) During None, (.%), (.%) 0,0 (.%), (.%), (.%) < 0.00 <0.00 ICS,0 (.%) (0.%) (0.%) 0 (0.%) (0.%) < ICS+LABA,0 (.%) 0 (.0%) (0.%) (0.%) (0.%) < LTRA, (.%), (.%), (.%) (0.%) (0.%) < 0.00 <0.00 ICS+LTRA,0 (.%) (0.%) 0 (0.%) (0.%) (0.%) < 0.00 <0.00 ICS+LABA+LTRA, (.%) (0.%) (0.%) 0 (0.%) 0 (0.%) < 0.00 <0.00 ICS: inhaled corticosteroids, LABA: long-acting β-agonists, SABA: short-acting β-agonists, LTRA: leukotriene receptor antagonists on March 0 by guest. Protected by copyright. - P value Trend during pregnancy : first published as 0./bmjopen-0-00 on November 0. Downloaded from
35 Page of DISCUSSION This study showed a prevalence of asthma requiring healthcare utilization during pregnancy of 0.% in South Korea. In a field survey conducted more than 0 years ago of a randomly recruited general population from cities and rural areas in Korea, the prevalence of current asthma, defined as current wheezing and positive bronchial hyper-responsiveness, in participants years old was approximately %. Considering that only a small percentage of patients seek healthcare services, the prevalence in our study may be reasonable. The prevalence of asthma during pregnancy was comparable to or slightly lower than that in the previous report in which, based on the insurance database, the prevalence of asthma in the Korean general population aged 0 years was reportedly.. cases per,000 persons. Significant numbers of pregnant women with asthma experienced severe exacerbations in our study. Among the women who were diagnosed with asthma,.% visited the emergency room or were admitted to a hospital for asthma treatment, while.% were also treated with systemic steroids and SABA, findings that are consistent with the results of previous studies. - This finding could be associated with the general low rate of asthma medication use during pregnancy. Among the,0 patients with suspected asthma who were diagnosed with asthma within years before pregnancy, only.% were prescribed asthma drugs at least once. The most common drugs prescribed for asthma during pregnancy in South Korea were ICS or ICS/LABA, similar to those administered to non-pregnant patients with asthma. When ICS alone was used, budesonide was more commonly selected during pregnancy than fluticasone, although fluticasone/salmeterol was more widely chosen than budesonide/formoterol. This phenomenon might be influenced by the result of a subgroup analysis of a randomized controlled trial in which the safety of budesonide during pregnancy - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
36 Page of was demonstrated. The adherence rate with prescription drugs is relatively low,,0 and pregnant women with asthma are no exception., In our study, many women may have stopped taking antiasthmatic drugs after becoming pregnant, possibly due to concerns that they could affect pregnancy outcomes. In fact, the US Food and Drug Administration categorizes the majority of asthma drugs including fluticasone, salmeterol, fluticasone/salmeterol, formoterol, budesonide/formoterol, salbutamol, theophylline, and prednisolone into category C (risk not ruled out). However, it is widely accepted that it is safer for pregnant women with asthma to be treated with asthma medications than continue to have asthma symptoms and exacerbations. Although no drug can be considered completely safe, 0 the major antiasthmatic drugs are generally considered safe - and uncontrolled asthma may be associated with poorer pregnancy outcomes.,, In fact, the guidelines state that poorly controlled asthma and exacerbations put babies at much greater risk than do current asthma treatments. In our study, a significant number of women were likely to stop anti-asthmatic drugs and substantial number of asthmatic pregnant women did experience exacerbations, which might indirectly support the guidelines emphasis on the adherence for asthma treatment during pregnancy. The limitations of our study include that only a portion of our pregnant cohort had asthma requiring healthcare utilization. Because this study was based on a claims database and not a survey, some pregnant women with mild or well-controlled asthma who did not need to seek medical attention may not have been included in the analysis. It is well known that similar percentages of women have improved, unchanged, and worsened asthmatic symptoms during pregnancy. In addition, pregnant women who were not covered by NHI or NMA were not included in this study. Moreover, our data should be cautiously interpreted. First, the analyses - : first published as 0./bmjopen-0-00 on November 0. Downloaded from on March 0 by guest. Protected by copyright.
CONSORT 2010 checklist of information to include when reporting a randomised trial*
CONSORT 2010 checklist of information to include when reporting a randomised trial* Section/Topic Title and abstract Introduction Background and objectives Item No Checklist item 1a Identification as a
More informationThe Safety of Asthma and Allergy Medications in Pregnancy: New Horizons
The Safety of Asthma and Allergy Medications in Pregnancy: New Horizons Jennifer Namazy, MD Division of Allergy Scripps Clinic, San Diego Michael Schatz, MD, MS Department of Allergy Kaiser Permanente,
More informationAsthma in Pregnancy. Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA. Introduction
Asthma in Pregnancy Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA Introduction Asthma is the most common potentially serious medical problem to complicate
More informationAssessment of knowledge and education relating to asthma during pregnancy among women of childbearing age
Al Ghobain et al. Asthma Research and Practice (2018) 4:2 DOI 10.1186/s40733-017-0038-x RESEARCH Open Access Assessment of knowledge and education relating to asthma during pregnancy among women of childbearing
More informationResearch Article Effect of Pregnancy on Quantitative Medication Use and Relation to Exacerbations in Asthma
Hindawi BioMed Research International Volume 2017, Article ID 8276190, 15 pages https://doi.org/10.1155/2017/8276190 Research Article Effect of Pregnancy on Quantitative Medication Use and Relation to
More informationA study of neonatal and maternal outcomes of asthma during pregnancy
International Journal of Research in Medical Sciences Meena BL et al. Int J Res Med Sci. 2013 Feb;1(1):23-27 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: 10.5455/2320-6012.ijrms20130206
More informationComorbidome, Pattern, and Impact of Asthma-COPD Overlap Syndrome in Real Life
Comorbidome, Pattern, and Impact of Asthma-COPD Overlap Syndrome in Real Life Job F. M. van Boven, PharmD, PhD; Miguel Román-Rodríguez, MD; Josep F. Palmer, MD; Núria Toledo-Pons, MD; Borja G. Cosío, MD,
More informationAsthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION
Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy Effects of asthma on pregnancy outcomes Effects of pregnancy on asthma control Management
More informationTreatment adjustment using a marker of airway inflammation reduces the exacerbation rate in pregnancy.
Credit: istockphoto. Key points Asthma is the most common chronic disease to affect pregnant women. Exacerbations occur in up to 45% of pregnant women with asthma. Asthma should be managed during pregnancy
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2016?
Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationAsthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes ...
169 OCCASIONAL REVIEW Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes V E Murphy, V L Clifton, P G Gibson... Exacerbations of asthma during pregnancy represent
More informationLong Term Care Formulary RS -29
RESTRICTED USE Asthma/COPD Management 1 of 6 PROTOCOL: Asthma Glossary of Medication Acronyms: SABA: short-acting beta agonist (e.g. salbutamol) SABD: short-acting bronchodilator (e.g. ipratropium or SABA)
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2015?
Global Initiative for Asthma (GINA) What s new in GINA 2015? GINA Global Strategy for Asthma Management and Prevention What s new in GINA 2015 (1) Add-on tiotropium by soft-mist inhaler is a new other
More informationOnline supplementary material
Online supplementary material Add-on long-acting β2-agonist (LABA) in a separate inhaler as asthma step-up therapy versus increased dose of inhaled corticosteroid (ICS) or ICS/LABA combination inhaler
More informationEvaluation of Asthma Management in Middle EAst North Africa Adult population
STUDY REPORT SUMMARY Evaluation of Asthma Management in Middle EAst North Africa Adult population Descriptive study on the management of asthma in an asthmatic Middle East Africa adult population Background/Rationale:
More informationUse of nicorandil is Associated with Increased Risk for Gastrointestinal Ulceration and Perforation- A Nationally Representative Populationbased
Use of nicorandil is Associated with Increased Risk for Gastrointestinal Ulceration and Perforation- A Nationally Representative Populationbased study Chien-Chang Lee, Shy-Shin Chang, Shih-Hao Lee, Yueh-Sheng
More informationAdherence to asthma controller medication regimens
Respiratory Medicine (2005) 99, 1263 1267 Adherence to asthma controller medication regimens D.A. Stempel a,, S.W. Stoloff b, J.R. Carranza Rosenzweig c, R.H. Stanford c, K.L. Ryskina d, A.P. Legorreta
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationAsthma Population Management: Identifying Persistent Asthma, Defining High Risk Asthma, and Measuring Quality of Asthma Care
Asthma Population Management: Identifying Persistent Asthma, Defining High Risk Asthma, and Measuring Quality of Asthma Care Michael Schatz, MD, MS Allergy Department Kaiser Permanente, San Diego, CA Constructs
More informationThe new england journal of medicine. The Clinical Problem. Strategies and Evidence
The new england journal of medicine Asthma in Pregnancy Michael Schatz, M.D., and Mitchell P. Dombrowski, M.D. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence
More informationNationwide pulmonary function test rates in South Korean asthma patients
Original Article Nationwide pulmonary function test rates in South Korean asthma patients Joon Young Choi 1, Hyoung Kyu Yoon 2, Jae Ha Lee 3, Kwang Ha Yoo 4, Bo Yeon Kim 5, Hye Won Bae 5, Young Kyoon Kim
More informationNevada Journal of Public Health, (2010). Vol. 7 Shen et al., 27
Nevada Journal of Public Health, (2010). Vol. 7 Shen et al., 27 Adverse Maternal Outcomes in Nevada: Does Asthma Matter? Jay J. Shen, Ph.D. Department of Health Care Administration and Policy School of
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationPolicy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists
Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: Step Therapy Prior
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationThe National Asthma Education and Prevention Program s
Long-Acting b-agonist Among Children and Adults With Asthma Elizabeth A. Wasilevich, PhD, MPH; Sarah J. Clark, MPH; Lisa M. Cohn, MS; and Kevin J. Dombkowski, DrPH Managed Care & Healthcare Communications,
More informationComprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma
Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma Pharmacoepidemiology Unit July 10, 2014 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2017?
Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome
More informationA Comprehensive Analysis of Adverse Obstetric and Pediatric Complications in Women with Asthma
A Comprehensive Analysis of Adverse Obstetric and Pediatric Complications in Women with Asthma Laila J. Tata 1, Sarah A. Lewis 2, Tricia M. McKeever 1, Chris J. P. Smith 2, Pat Doyle 3, Liam Smeeth 3,
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationHow far are we from adhering to national asthma guidelines: The awareness factor
Egyptian Journal of Ear, Nose, Throat and Allied Sciences (2013) 14, 1 6 Egyptian Society of Ear, Nose, Throat and Allied Sciences Egyptian Journal of Ear, Nose, Throat and Allied Sciences www.ejentas.com
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationBMJ Open. For peer review only -
Self Reported Feelings Of Anger And Aggression Towards Others In Patients On Levetiracetam: A Cohort study using the UK Anti Epileptic Drug Register Journal: BMJ Open Manuscript ID: bmjopen-0-00 Article
More informationReal-Life Clinical Use of Symbicort Maintenance and Reliever Therapy for Asthmatic Patients in Korea
Brief Communication Allergy Asthma Immunol Res. 2018 January;10(1):88-94. https://doi.org/10.4168/aair.2018.10.1.88 pissn 2092-7355 eissn 2092-7363 Real-Life Clinical Use of Symbicort Maintenance and Reliever
More informationComparison of clinical characteristics and management of asthma by types of health care in South Korea
Original Article Comparison of clinical characteristics and management of asthma by types of health care in South Korea Eun Yeong Cho 1#, Ki Jong Oh 2#, Chin Kook Rhee 3, Kwang Ha Yoo 4, Bo Yeon Kim 5,
More informationResearch Article Use of Antiasthmatic Drugs during Pregnancy after the First Trimester and Maternal and Neonatal Outcomes
Respiratory Medicine, Article ID 209583, 7 pages http://dx.doi.org/10.1155/2014/209583 Research Article Use of Antiasthmatic Drugs during Pregnancy after the First Trimester and Maternal and Neonatal Outcomes
More informationPlacental steroid receptors and sex differences in fetal growth
Placental steroid receptors and sex differences in fetal growth Professor Vicki Clifton Mater Medical Research Institute University of Queensland Brisbane, Australia Sex differences start in utero Lying-in
More informationKirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo,
Kirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo, BRONCHODILATORS: Beta Adrenoreceptor Agonists Actions Adrenoreceptor agonists have many of the same actions as epinephrine/adrenaline,
More informationThe Diabetes Epidemic in Korea
Review Article Endocrinol Metab 2016;31:349-33 http://dx.doi.org/.3803/enm.2016.31.3.349 pissn 2093-96X eissn 2093-978 The Diabetes Epidemic in Korea Junghyun Noh Department of Internal Medicine, Inje
More informationCHARM ASTHMA TREATMENT GUIDELINE
NHS City and Hackney Prescribing Guidelines Adults ( 12 years of age) CHARM ASTHMA TREATMENT GUIDELINE Written by: Hetal Dhruve (Specialist Respiratory Pharmacist, City and Hackney CCG) Checked by: Prof
More informationInhaled Corticosteroid vs. Add-On Long-Acting Beta-Agonist for Step-Up Therapy in Asthma
Online Data Supplement Inhaled Corticosteroid vs. Add-On Long-Acting Beta-Agonist for Step-Up Therapy in Asthma Elliot Israel, Nicolas Roche, Richard J. Martin, Gene Colice, Paul M. Dorinsky, Dirkje S.
More informationBMJ Open. Risk Factors of Asthma Exacerbation Based on Asthma Severity: A Nationwide Population-based Observational Study in South Korea
Risk Factors of Asthma Exacerbation Based on Asthma Severity: A Nationwide Population-based Observational Study in South Korea Journal: Manuscript ID bmjopen-0-00 Article Type: Research Date Submitted
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationCHECK-LISTS AND Tools DR F. R E Z A E I DR E. G H A D E R I K U R D I S TA N U N I V E R S I T Y O F M E D I C A L S C I E N C E S
CHECK-LISTS AND Tools DR F. R E Z A E I DR E. G H A D E R I K U R D I S TA N U N I V E R S I T Y O F M E D I C A L S C I E N C E S What is critical appraisal? Critical appraisal is the assessment of evidence
More informationDr Christopher Worsnop
Dr Christopher Worsnop Respiratory & Sleep Physician Austin Hospital, Melbourne Supported by: Top Tips in Modern Asthma Management Dr Christopher Worsnop Rotorua GPCME Meeting June 2013 Speaker declaration
More informationOriginal Article. ARTICLE INFO Article history: Received 9 September 2017 Received in revised form 19 November 2017 Accepted 20 November 2017
Original Article Pharm Sci Asia 2018; 45 (1), 13-21 DOI : 10.29090/psa.2018.01.013 Investigation on medication use and factors associated with levels of asthma control among asthmatic outpatients at University
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationImplications of Changes in FDA Prescribing Information Regarding the Safety and Use of
Page 1 of 21 Implications of Changes in FDA Prescribing Information Regarding the Safety and Use of Asthma Biologics during Pregnancy Michael Schatz 1, MD, MS, ATSF, Jerry A. Krishnan 2, MD, PhD, ATSF,
More informationThe Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia.
The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. Rennard, Stephen I; Sin, Donald D; Tashkin, Donald P; Calverley, Peter M; Radner, Finn Published in: Annals
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationIs reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is reslizumab effective in improving
More informationGSK Medicine: salmeterol, Salmeterol+Fluticasone proprionate, fluticasone propionate, beclomethasone
GSK Medicine: salmeterol, Salmeterol+Fluticasone proprionate, fluticasone propionate, beclomethasone Study No.: WWE111984/WEUSRTP2640/EPI40528 Title: The Asthma Death Case Control Study (ADCCS): Association
More informationFour of 10 patients with asthma suffer moderate REVIEW DUAL-CONTROLLER REGIMENS II: OBSERVATIONAL DATA. Michael S. Blaiss, MD ABSTRACT
DUAL-CONTROLLER REGIMENS II: OBSERVATIONAL DATA Michael S. Blaiss, MD ABSTRACT The differences between clinical trials and clinical practice often create difficulty for generalizing results of controlled
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationThe impacts of cognitive impairment on acute exacerbations of chronic obstructive pulmonary disease
The impacts of cognitive impairment on acute exacerbations of chronic obstructive pulmonary disease Dr. Lo Iek Long Department of Respiratory Medicine C.H.C.S.J. Chronic Obstructive Pulmonary Disease (COPD)
More informationInhaled Hypertonic Saline In Adults Hospitalized For Exacerbation Of Cystic Fibrosis Lung Disease: A Retrospective Study For peer review only
BMJ Open Inhaled Hypertonic Saline In Adults Hospitalized For Exacerbation Of Cystic Fibrosis Lung Disease: A Retrospective Study Journal: BMJ Open Manuscript ID: bmjopen--0000 Article Type: Research Date
More informationfluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK
fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK 09 May 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationThis is the publisher s version. This version is defined in the NISO recommended practice RP
Journal Article Version This is the publisher s version. This version is defined in the NISO recommended practice RP-8-2008 http://www.niso.org/publications/rp/ Suggested Reference Chong, J., Karner, C.,
More informationAsthma training. Mike Levin Division of Asthma and Allergy Red Cross Hospital
Asthma training Mike Levin Division of Asthma and Allergy Red Cross Hospital Introduction Physiology Diagnosis Severity Treatment Control Stage 3 of guidelines Acute asthma Drug delivery Conclusion Overview
More informationAsthma self-management skills and the use of asthma education during pregnancy
Eur Respir J 2005; 26: 435 441 DOI: 10.1183/09031936.05.00135604 CopyrightßERS Journals Ltd 2005 Asthma self-management skills and the use of asthma education during pregnancy V.E. Murphy*, P.G. Gibson*,
More informationSlow-Release Theophylline in Pregnant Asthmatics*
Slow-Release in Pregnant Asthmatics* Brita Stenius-Aarniala, MD, FCCP; Seija Riikonen, MD; and Kari Teramo, MD Study objective: Oral theophylline treatment may be helpful in controlling severe asthma during
More informationCME/CE POSTTEST CME/CE QUESTIONS
CME/CE POSTTEST CME/CE QUESTIONS Controlling Asthma Severity: Identifying Unmet Needs and Optimizing Therapeutic Options There are no fees for participating in and receiving continuing medical education
More informationAsthma in Pregnancy, Labour and Postnatal Guidelines
Asthma in Pregnancy, Labour and Postnatal Guidelines N.B. Staff should be discouraged from printing this document. This is to avoid the risk of out of date printed versions of the document. The Intranet
More informationInterventions to improve adherence to inhaled steroids for asthma. Respiratory department
Interventions to improve adherence to inhaled steroids for asthma Respiratory department Content Overview Research References Overview Asthma is a chronic breathing condition that affects more than 300
More informationPregnancy outcomes in Korean women with diabetes
Pregnancy outcomes in Korean women with diabetes Sung-Hoon Kim Department of Medicine, Cheil General Hospital & Women s Healthcare Center, Dankook University College of Medicine, Seoul, Korea Conflict
More informationEpidemiologic characteristics of cervical cancer in Korean women
Review Article J Gynecol Oncol Vol. 25, No. 1:70-74 pissn 2005-0380 eissn 2005-0399 Epidemiologic characteristics of cervical cancer in Korean women Hyun-Joo Seol, Kyung-Do Ki, Jong-Min Lee Department
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationThe methodology behind GINA and EPR-3 medication recommendations: Stepwise treatment in asthma
The methodology behind GINA and EPR-3 medication recommendations: Stepwise treatment in asthma Maureen George PhD RN AE-C FAAN Columbia University mg3656@cumc.columbia.edu Faculty Disclosures Maureen George
More informationEndobronchial Thermoplasty
Endobronchial Thermoplasty Asthma Education Day Thursday, October 30, 2014 Cynthia Ray, MD, FCCP Senior Staff Physician Interventional Pulmonology Pulmonary and Critical Care Medicine Henry Ford Hospital
More informationASTHMA IN THE PEDIATRIC POPULATION
ASTHMA IN THE PEDIATRIC POPULATION SEARCH Rotation 2 August 23, 2010 Objectives Define asthma as a chronic disease Discuss the morbidity of asthma in pediatrics Discuss a few things that a health center
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationImproving the Management of Asthma to Improve Patient Adherence and Outcomes
Improving the Management of Asthma to Improve Patient Adherence and Outcomes Robert Sussman, MD Atlantic Health System Overlook Medical Center Asthma Remains a Serious Health Risk in the US Every day in
More informationbeclometasone 100 MDI 2 puffs twice a day (recently changed to non CFC (Clenil Modulite))
Case 1 Mr Thomson, a 32 year old asthmatic who is well known to you comes into your pharmacy. He is known to have a best peak flow of 640 L/min. He tells you that over the last few weeks he has been wakening
More informationThe use of controller medications management of pediatric bronchial asthma -
Original Research Article The use of controller medications in the management of pediatric bronchial asthma - Dynamic patterns of LTRA Anna Todorova 1*, Antoaneta Tsvetkova 2, Silvia Mihaylova 2 1 Faculty
More informationScottish Medicines Consortium
Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)
More informationOvercome Asthma! Asthma in the elderly
2016 APAAACI Overcome Asthma! Asthma in the elderly Sang-Heon Cho, MD, PhD Department of Internal Medicine Seoul National University College of Medicine Seoul, Korea Elderly asthma : still we do not know
More informationGetting Asthma treatment right. Dr David Cremonesini Specialist Pediatrician American Hospital
Getting Asthma treatment right Dr David Cremonesini Specialist Pediatrician American Hospital cdavid@ahdubai.com } Consultant Paediatrician from UK of 5.5 years } Speciality in Allergy / Asthma (PG Certificate)
More informationUS max daily dose i Food and Drug Administration [2]
APPENDIX 2 etable 1. Regulatory limits on total daily dose for asthma medications Drugs Canadian max daily dose i Health Canada [1] US max daily dose i Food and Drug Administration [2] European max daily
More informationTHE ROLE OF INDOOR ALLERGEN SENSITIZATION AND EXPOSURE IN CAUSING MORBIDITY IN WOMEN WITH ASTHMA
Online Supplement for: THE ROLE OF INDOOR ALLERGEN SENSITIZATION AND EXPOSURE IN CAUSING MORBIDITY IN WOMEN WITH ASTHMA METHODS More Complete Description of Study Subjects This study involves the mothers
More informationBreakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom
Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom 2 BEYOND SYMPTOMS ADDRESSING FUTURE RISK IN ASTHMA South GP CME 2013,
More informationInclude patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more.
Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group rthampton General Hospital NHS Trust rthamptonshire Healthcare Foundation Trust Stepping down asthma
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationAdjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older
Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older The Canadian Thoracic Society and other international asthma
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationGreater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationPatterns, predictors and outcomes of asthma control and exacerbations during pregnancy: a prospective cohort study
ORIGINAL ARTICLE ASTHMA Patterns, predictors and outcomes of asthma control and exacerbations during pregnancy: a prospective cohort study Luke E. Grzeskowiak 1, Brian Smith 2, Anil Roy 2, Gustaaf A. Dekker
More informationEndobronchial Thermoplasty
Endobronchial Thermoplasty Michigan Society for Respiratory Care Monday, October 5, 2015 Cynthia Ray, MD, FCCP Senior Staff Physician Interventional Pulmonology Pulmonary and Critical Care Medicine Henry
More informationCONSORT 2010 Statement Annals Internal Medicine, 24 March History of CONSORT. CONSORT-Statement. Ji-Qian Fang. Inadequate reporting damages RCT
CONSORT-Statement Guideline for Reporting Clinical Trial Ji-Qian Fang School of Public Health Sun Yat-Sen University Inadequate reporting damages RCT The whole of medicine depends on the transparent reporting
More informationInhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years & over
Manufacturer Submission To The National Institute for Health and Clinical Excellence By GlaxoSmithKline UK Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years
More information(Asthma) Diagnosis, monitoring and chronic asthma management
Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic
More informationWEBINAR. Difficult-to-treat and severe asthma: changing the paradigm
WEBINAR Difficult-to-treat and severe asthma: changing the paradigm A multidisciplinary discussion on new therapies, and how to identify and manage difficult-to-treat and severe asthma DIFFICULT-TO-TREAT
More informationBritish Guideline on the Management of Asthma
British Guideline on the Management of Asthma A national clinical guideline British Thoracic Society Scottish Intercollegiate Guidelines Network Revised edition November 2005 British Guideline on the Management
More informationIn 2002, it was reported that 72 of 1000
REPORTS Aligning Patient Care and Asthma Treatment Guidelines Eric Cannon, PharmD Abstract This article describes how the National Asthma Education and Prevention Program Guidelines for the Diagnosis and
More informationAntidepressants. Professor Ian Jones May /WalesMentalHealth
Antidepressants Professor Ian Jones May 2017 www.ncmh.info @ncmh_wales /WalesMentalHealth 029 2074 4392 info@ncmh.info We identified 19 740 pregnancies exposed to an antidepressant at some point during
More informationActivities and Plans of GARD Korea
Activities and Plans of GARD Korea You-Young Kim M.D., Ph.D. Korea Asthma Allergy Foundation (KAF) GARD General Meeting, May 30-31 2008, Istanbul, Turkey Overview Burden of major chronic respiratory diseases
More information